Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
Anna SvedbergSvante VikingssonAnders VikströmNiels HornstraMagnus KentsonEva BrandenHirsh KoyiBengt BergmanHenrik GréenPublished in: British journal of clinical pharmacology (2019)
An induction of CYP3A activity was observed after 2 months of erlotinib treatment which was also seen when subdividing based on gender. It could be important to take this into consideration for patients co-administering other CYP3A-metabolizing drugs during erlotinib treatment and also makes it difficult to use baseline CYP3A activity to predict erlotinib pharmacokinetics.